NEXGEL and STADA AG Announce Expansion of Partnership for North America
NEXGEL (NASDAQ:NXGL), a hydrogel products manufacturer, has expanded its partnership with STADA Arzneimittel AG for the North American market. The collaboration focuses on launching digestive enzyme formulas and solutions for scars and stretch marks.
As part of this strategic expansion, STADA will provide $1 million in non-dilutive capital to support NEXGEL's product launches and marketing initiatives. The partnership aims to bring innovative health solutions to North American consumers, leveraging NEXGEL's expertise in high-water-content hydrogel products and STADA's position as a European consumer health leader.
NEXGEL (NASDAQ:NXGL), produttore di prodotti in idrogel, ha ampliato la sua collaborazione con STADA Arzneimittel AG per il mercato nordamericano. La partnership si concentra sul lancio di formule enzimatiche digestive e soluzioni per cicatrici e smagliature.
Come parte di questa espansione strategica, STADA fornirà 1 milione di dollari in capitale non diluitivo per supportare i lanci di prodotti e le iniziative di marketing di NEXGEL. L'obiettivo della collaborazione è offrire soluzioni innovative per la salute ai consumatori nordamericani, sfruttando l'esperienza di NEXGEL nei prodotti in idrogel ad alto contenuto d'acqua e la posizione di STADA come leader europeo nel settore della salute dei consumatori.
NEXGEL (NASDAQ:NXGL), fabricante de productos de hidrogel, ha ampliado su colaboración con STADA Arzneimittel AG para el mercado norteamericano. La alianza se centra en el lanzamiento de fórmulas de enzimas digestivas y soluciones para cicatrices y estrías.
Como parte de esta expansión estratégica, STADA proporcionará 1 millón de dólares en capital no dilutivo para apoyar los lanzamientos de productos y las iniciativas de marketing de NEXGEL. La colaboración busca ofrecer soluciones innovadoras de salud a los consumidores norteamericanos, aprovechando la experiencia de NEXGEL en productos de hidrogel con alto contenido de agua y la posición de STADA como líder europeo en salud del consumidor.
NEXGEL (NASDAQ:NXGL)은 하이드로겔 제품 제조업체로서 북미 시장을 위해 STADA Arzneimittel AG와의 파트너십을 확장했습니다. 이번 협력은 소화 효소 포뮬러와 흉터 및 스트레치 마크용 솔루션 출시를 중심으로 진행됩니다.
이 전략적 확장의 일환으로 STADA는 NEXGEL의 제품 출시 및 마케팅 활동을 지원하기 위해 100만 달러의 비희석성 자본을 제공할 예정입니다. 이 파트너십은 NEXGEL의 고수분 함유 하이드로겔 제품 전문성과 STADA의 유럽 소비자 건강 분야 리더십을 활용해 북미 소비자들에게 혁신적인 건강 솔루션을 제공하는 것을 목표로 합니다.
NEXGEL (NASDAQ:NXGL), fabricant de produits hydrogel, a étendu son partenariat avec STADA Arzneimittel AG pour le marché nord-américain. Cette collaboration vise à lancer des formules d'enzymes digestives ainsi que des solutions pour les cicatrices et les vergetures.
Dans le cadre de cette expansion stratégique, STADA apportera 1 million de dollars en capital non dilutif pour soutenir les lancements de produits et les initiatives marketing de NEXGEL. Ce partenariat a pour objectif d'offrir des solutions de santé innovantes aux consommateurs nord-américains, en tirant parti de l'expertise de NEXGEL dans les produits hydrogel à haute teneur en eau et de la position de STADA en tant que leader européen de la santé grand public.
NEXGEL (NASDAQ:NXGL), ein Hersteller von Hydrogel-Produkten, hat seine Partnerschaft mit STADA Arzneimittel AG für den nordamerikanischen Markt ausgeweitet. Die Zusammenarbeit konzentriert sich auf die Einführung von Verdauungsenzym-Formulierungen sowie Lösungen für Narben und Dehnungsstreifen.
Im Rahmen dieser strategischen Erweiterung wird STADA 1 Million US-Dollar an nicht verwässerndem Kapital bereitstellen, um die Produkteinführungen und Marketinginitiativen von NEXGEL zu unterstützen. Ziel der Partnerschaft ist es, innovative Gesundheitslösungen für nordamerikanische Verbraucher bereitzustellen, wobei NEXGELs Expertise in hydrogelbasierten Produkten mit hohem Wasseranteil und STADAs Position als europäischer Marktführer im Bereich der Verbrauchergesundheit genutzt werden.
- Secured $1 million in non-dilutive capital from STADA
- Strategic expansion into new product categories (digestive enzymes and skin solutions)
- Partnership with established European consumer health leader enhances market reach
- None.
LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. The expansion includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks.
As part of the agreement, STADA will advance
“This next phase of our partnership reflects a shared outlook that there is an opportunity in bringing these health solutions to consumers across North America,” said Adam Levy, Chief Executive Officer of NEXGEL. “We are grateful for STADA’s financial support, which will accelerate our joint go-to-market strategy.”
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2024, STADA achieved group sales of
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
NEXGEL Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@kcsa.com
FAQ
What is the new partnership between NEXGEL (NXGL) and STADA AG?
How much funding did NEXGEL (NXGL) receive from STADA AG in July 2025?
What new products will NEXGEL (NXGL) launch with STADA AG?
What is NEXGEL's (NXGL) main business focus?
